Jennifer Low

Dr. Jennifer Low is a drug development strategy consultant, and is currently Acting Chief Medical Officer for ORIC Pharmaceuticals. Previously, she was the Chief Medical Officer and Executive Vice President, Research and Development at Loxo Oncology, and before that she was Senior Group Director at Genentech/Roche, where she oversaw the Erivedge (hedgehog), Zelboraf (b-RAF), Cotellic (mek), and Tarceva (EGFR) programs in oncology development.

She received her undergraduate degree from Caltech, her MD and PhD degrees from Georgetown, and completed her internal medicine residency at UC Davis, her medical oncology fellowship at the National Cancer Institute, and was a Senior Investigator at the Cancer Therapeutics Evaluation Program (CTEP) at NCI and an attending physician in breast cancer at NIH and the National Naval Medical Center in Bethesda. She has co-authored papers appearing in the New England Journal of Medicine, Science, Journal of Clinical Oncology, and Nature Reviews Cancer.